Cefuroxime Sodium for Injection

This product is a second-generation cephalosporin antibiotic. The antibacterial activity of ceftriaxone sodium is only 1/5 (1/10) of that of cefamandole. Ceftriaxone sodium is rapidly hydrolyzed into ceftriaxone after entering the body, so the antibacterial effects of the two in the body are basically the same. Ceftriaxone has a strong antibacterial effect on most Gram-positive cocci, and its activity is similar to that of cephalothin and cefazolin. Enterococci and methicillin-resistant Staphylococcus aureus are resistant to this product. This product has a good effect on diphtheria Corynebacterium and Gram-positive anaerobic bacteria (anaerobic cocci and Clostridium), and has a relatively strong activity against Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae and Haemophilus influenzae. It has strong antibacterial effects on spore-forming agents and cefazolin. Some Enterobacter aerogenes, indole-positive Proteus and Providencia are sensitive to this product. Salmonella typhi, Shigella, Neisseria gonorrhoeae and Neisseria meningitidis are also very sensitive to this product, but its antibacterial effect on Bacteroides fragilis is poor. Serratia, Alcaligenes, Acinetobacter and Pseudomonas aeruginosa are resistant to this product. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, make the bacteria elongate, and finally dissolve and die.

The main ingredient of this product is cefuroxime sodium.

It is suitable for lung infections, urinary tract infections, bile tract infections, skin and soft tissue infections, bone and joint infections, sepsis, abdominal infections, etc. caused by sensitive bacteria.

The daily dose for adults is 2.0-8.0 g for intramuscular injection, slow intravenous injection (3-5 minutes) or intravenous drip, which is administered in 3-4 times. The maximum daily dose does not exceed 12 g. For skin infections, uncomplicated pneumonia and urinary tract infections, 0.5-1 g every 6 hours is sufficient. For patients with renal impairment, the dose can be calculated according to creatinine clearance. First give the first dose of saturation (1-2 g), then give 2 g every 6 hours for patients with creatinine clearance greater than 50 ml/min, and 0.5 g every 6 hours and every 12 hours for patients with clearance rates of 25-50 ml/min and 10-25 ml/min, respectively. For patients with creatinine clearance less than 10 ml/min, the dose is 0.5 g every 24 hours. For infants and children over 1 month old, the daily dose is 50-100 mg/kg according to body weight, administered in 3-4 times, depending on the severity of infection.

The incidence of adverse reactions is about 7.8%, and there may be pain in the intramuscular injection area and thrombophlebitis, the latter of which is more severe than cephalothin. Allergic reactions are manifested as drug rash, eosinophilia, positive Coombs reaction, etc., and drug fever is occasionally seen. A small number of patients have increased serum aspartate aminotransferase, serum alanine aminotransferase, alkaline phosphatase, and serum creatinine, which are mostly temporary. There are also reports of reversible nephropathy caused by cefadroxil. A small number of patients may have bleeding tendencies caused by coagulation disorders when using large doses, and prothrombin time and bleeding time are prolonged, which is more common in patients with renal impairment. This is because this product interferes with the metabolism of vitamin K in the liver, leading to hypoprothrombinemia. Therefore, after stopping the drug and injecting vitamin K, the coagulation function can return to normal, and giving vitamin K at the same time can prevent the occurrence of this reaction.

It is contraindicated for newborns under 1 month old and premature infants; it is contraindicated for those who are allergic to cephalosporin antibiotics; it should be used with caution in pregnant and lactating women.

Precautions for children: Not suitable for newborns and premature infants under 1 month old. Precautions for pregnancy and lactation: Use with caution for pregnant and lactating women.

1. This product contains sodium carbonate, so it is incompatible with solutions containing calcium or magnesium (including compound sodium chloride injection or compound sodium lactate injection). The two cannot be mixed in the same container; if they must be used together, they should be administered separately in different containers. 2. The use of cefamandole with drugs that produce hypoprothrombinemia, thrombocytopenia or gastrointestinal ulcers will interfere with coagulation function and increase the risk of bleeding. 3. The use of cefamandole with aminoglycosides, polymyxins, furosemide, and ethacrynic acid may increase the possibility of nephrotoxicity. 4. Probenecid can inhibit the renal tubular secretion of cephalosporins. The simultaneous use of the two will increase the blood concentration of cephalosporins and prolong their half-life. 5. Erythromycin can increase the in vitro antibacterial activity of this product against Bacteroides fragilis by more than 100 times. When used in combination with gentamicin or amikacin, it has a synergistic effect against certain Gram-negative bacteria in vitro.

Keep tightly closed in a cool, dark and dry place.

Calculated as C18H18N6O5S2: 0.5g

Suzhou Chung- HWA Chemical & Pharmaceutical Industrial Co., Ltd.

• Founded in:

  1993-04-27

• Address:

  No. 66, Yong'an Road, Suzhou High-tech Zone

• Tax NO.:

  913205056081966464

• Registered Funds:

  $25.5 million

• Website:

  Log in to view

• Email:

  Log in to view